Pharma Stability: Insights, Guidelines, and Expertise
The purpose of this Standard Operating Procedure (SOP) is to outline the process for developing and validating a stability-indicating method for drug substances and drug products in accordance with the ICH Q2(R1) guidelines. This SOP ensures that the method developed is capable of accurately detecting stability-related changes over time.
Click to read the full article.
The purpose of this Standard Operating Procedure (SOP) is to define the procedure for conducting stability studies for drug substances in accordance with US FDA guidelines. This SOP ensures that the stability data generated is adequate to demonstrate the quality, safety, and efficacy of drug substances throughout their shelf life under intended storage conditions.
Click to read the full article.
The purpose of this Standard Operating Procedure (SOP) is to outline the process for evaluating stability data of drug substances and products in accordance with the ICH Q1E guidelines. This SOP ensures consistent and scientifically sound evaluation of stability data to establish the shelf life and storage conditions of pharmaceutical products.
Click to read the full article.
The purpose of this Standard Operating Procedure (SOP) is to outline the process for designing stability studies for combination products in accordance with relevant regulatory guidelines. This SOP ensures that stability studies provide adequate data to support the quality, safety, and efficacy of combination products.
Click to read the full article.
The purpose of this Standard Operating Procedure (SOP) is to provide a procedure for conducting stability studies of modified release drug products in accordance with US FDA and ICH guidelines. This SOP ensures that the stability data generated is suitable for supporting product quality, safety, and efficacy throughout its shelf life.
Click to read the full article.
The purpose of this Standard Operating Procedure (SOP) is to provide guidelines for documenting stability studies for New Drug Applications (NDAs) to the United States Food and Drug Administration (US FDA). This SOP ensures that stability data is presented in a manner consistent with US FDA regulatory requirements to support product approval.
Click to read the full article.
The purpose of this Standard Operating Procedure (SOP) is to provide guidelines for preparing stability study reports for Abbreviated New Drug Application (ANDA) submissions to the United States Food and Drug Administration (US FDA). This SOP ensures that stability data is presented in a manner that meets regulatory requirements and supports product approval.
Click to read the full article.
The purpose of this Standard Operating Procedure (SOP) is to outline the procedure for conducting stability testing of new dosage forms in accordance with the ICH Q1C guidelines. This SOP ensures that the stability data generated supports the quality, safety, and efficacy of new dosage forms throughout their shelf life.
Click to read the full article.
The purpose of this Standard Operating Procedure (SOP) is to outline the process for conducting stability testing for post-approval changes to drug substances and products in accordance with US FDA guidelines. This SOP ensures that any changes made after approval do not adversely affect the product’s quality, safety, or efficacy.
Click to read the full article.
The purpose of this Standard Operating Procedure (SOP) is to outline the process for developing and validating a stability-indicating method for drug substances and drug products in accordance with the ICH Q2(R1) guidelines. This SOP ensures that the method developed is capable of accurately detecting stability-related changes over time.
Click to read the full article.